In a phase I clinical trial, CD40 agonist mAb therapy in combination with gemcitabine resulted in tumor response in 19% of patients with unresectable chemotherapy naïve pancreatic cancer.62 Tumor biopsies from these patients showed a dearth of TIL and an abundance of tumor infiltrating macrophages.62 A second phase I study is aimed at studying the combination of anti‐CD40 therapy with nab‐paclitaxel and gemcitabine in pancreatic cancer and is currently enrolling (Table 1). This evidence concerns the gene CD40 and familial pancreatic carcinoma.